Poseida Therapeutics Inc (PSTX) USD0.0001
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company’s approach to cell and gene therapies is based on its genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. Its P-MUC1C-ALLO1 is an allogeneic CAR-T product candidate with the potential to treat a range of solid tumor indications, including breast and other epithelial-derived cancers. Its product candidate, P-PSMA- ALLO1, is being developed for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. Its P-CD19CD20-ALLO1 is an allogeneic, CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications.